Nutritional modulation of immunity and the inflammatory response

Nutrition

Volumn 14, Issue 6, 1998, Pages 545-550

  Lin, Edward ^a   Kotani, Joji G ^a   Lowry, Stephen F ^a,b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Cytokines; Fatty acids; Immunomodulation; Metabolism; Nucleotides; Systemic inflammatory response syndrome

Indexed keywords

FATTY ACID; GLUTAMINE; NUCLEOTIDE;

CELL METABOLISM; CONFERENCE PAPER; DIETARY INTAKE; ENERGY; FATTY ACID METABOLISM; HUMAN; IMMUNOCOMPETENCE; IMMUNOMODULATION; INFLAMMATION; MORTALITY; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; STARVATION; WOUND HEALING;

ANIMALS; CYTOKINES; DIGESTIVE SYSTEM; HUMANS; IMMUNITY; INFLAMMATION; NUTRITIONAL SUPPORT; STRESS; WOUNDS AND INJURIES;

EID: 0032101384     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(98)00046-X     Document Type: Conference Paper

References (56)

1. Howard L., Ament M., Fleming C.R., et al. Current use and clinical outcome of home parenteral and enteral nutrition therapies in the United States. Gastroenterology. 109:1995;355.
2. Kudsk K.A., Minard G., Croce M.A., et al. A randomized trial of isonitrogenous enteral diets after severe trauma an immune-enhancing diet reduces septic complications . Ann Surg. 224:1996;531.
3. Perioperative total parenteral nutrition in surgical patients. N Engl J Med. 325:1991;525.
4. Chiolero R., Revelly J.P., Tappy L. Energy metabolism in sepsis and injury. Nutrition. 13:1997;45S.
5. Katz J.A., Lowry S.F. Substrate utilization in hypermetabolism. Fein A.M., Abraham E., Balk R., Bernard G., Dantzker D., Fink M. Sepsis and multiorgan failure. 1998;96 Williams & Wilkins, Philadelphia.
6. Guirao X., Lowry S.F. Biologic control of injury and inflammation much more than too little or too late . World J Surg. 20:1996;437.
7. Marshall J.C., Cook D.J., Christou N.V., Bernard G.R., Sprung C.L., Sibbald W.J. Multiple organ dysfunction score a reliable descriptor of a complex clinical outcome . Crit Care Med. 23:1995;1638.
8. Lin E., Calvano S.E., Lowry S.F. The biologic control of systemic inflammatory response. Curr Opin Crit Care. 3:1997;299.
9. Thompson W.A., Lowry S.F. Effect of nutrition on inflammatory mediators. Zaloga G. Nutrition in critical care. 1994;505 Mosby, St. Louis.
10. Lin E., Calvano S.E., Lowry S.F. Cytokine response in abdominal surgery. Schein M., Wise L. Cytokines and the abdominal surgeon. 1998;47 Landes, Austin.
11. Van der Poll T., Lowry S.F. Tumor necrosis factor in sepsis mediator of multiple organ failure or essential part of host defense? Shock. 3:1995;1.
12. Van der Poll T., Lowry S.F. Endogenous mechanisms regulating TNF and IL-1 during sepsis. Vincent J.L. Yearbook of intensive care and emergency medicine. 1995;385 Springer-Verlag, Berlin.
13. Lowry S.F., Calvano S.E. Soluble cytokine and hormonal mediators of immunity and inflammation. Howard R.J., Simmons R.L. Surgical infectious diseases. 3rd ed. 1995;313 Appleton and Lange, Norwalk, Connecticut.
14. Rogy M.A., Coyle S.M., Oldenburg H.S.A., et al. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg. 178:1994;132.
15. Van Zee K.J., Kohno T., Fischer E., Rock C.S., Moldawer L.L., Lowry S.F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA. 89:1992;4845.
16. Aderka D., Engelmann H., Maor Y., Brakebusch C., Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 175:1992;323.
17. Fong Y., Tracey K.J., Moldawer L.L., et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin-1β and interleukin-6 appearance during lethal bacteremia. J Exp Med. 170:1989;1627.
18. Granowitz E.V., Santos A.A., Poutsiaka D.D., et al. Production of interleukin-1 receptor antagonist during experimental endotoxaemia. Lancet. 338:1991;1423.
19. Van der Poll T., van Deventer S.J.H., ten Cate H., Levi M., ten Cate J.W. Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia. J Infect Dis. 169:1994;665.
20. Fischer E., van Zee K.J., Marano M.A., et al. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood. 79:1992;2196.
21. Van der Poll T., Fisher E., Coyle S.M., et al. Interleukin-1 contributes to increased concentrations of soluble tumor necrosis factor receptor type I in sepsis. J Infect Dis. 172:1995;577.
22. Leng S.X., Elias J.A. Interleukin-11 inhibits macrophage interleukin-12 production. J Immunol. 159:1997;2161.
23. Alleva D.G., Kaser S.B., Monroy M.A., Fenton M.J., Beller D.I. IL-15 functions as a potent autocrine regulator of macrophage proinflammatory cytokine production. J Immunol. 159:1997;2941.
24. Karres I., Kremer J.P., Steckholzer U., Kenney J.S., Ertel W. Transforming growth factor-β1 inhibits synthesis of cytokines in endotoxin-stimulated human whole blood. Arch Surg. 131:1996;1310.
25. Casey L.C., Balk R.A., Bone R.C. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 119:1993;771.
26. Meduri G.U., Headley S., Kohler G., et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS Plasma IL-1β and IL-6 levels are consistent and efficient predictors of outcome over time . Chest. 107:1995;1062.
27. Kotani G., Usami M., Kasahara H., Saitoh Y. The relationship of IL-6 hormonal mediators, fuel utilization, and systemic hypermetabolism after surgical trauma. Kobe J Med Sci. 42:1996;187.
28. Schindler R., Mancilla J., Endres S., Ghorbani R., Clark R., Dinarello C.A. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells IL-6 suppresses IL-1 and TNF . Blood. 75:1990;40.
29. Tilg H., Trehu E., Atkins M.B., Dinarello C.A., Mier J.W. Interleukin-6 (IL-6) as an antiinflammatory cytokine induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55 . Blood. 83:1994;113.
30. Oldenburg H.S.A., Rogy M.A., Lazarus D.D., et al. Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6. Eur J Immunol. 23:1993;1889.
31. Berger D., Bolke E., Seidelmann M., et al. Time-scale of interleukin-6, myeloid related proteins (MRP), C-reactive protein (CRP), and endotoxin plasma levels during the postoperative acute phase reaction. Shock. 7:1997;422.
32. Lee A., Whyte K.B., Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol. 54:1993;283.
33. Biffl W.L., Moore E.E., Moore F.A., et al. Interleukin-6 delays neutrophil apoptosis. Arch Surg. 131:1996;24.
34. Marchant A., Deviere J., Byl B., de Grootte D., Vincent J.L., Goldman M. Interleukin-10 production during septicaemia. Lancet. 343:1994;707.
35. Van der Poll T., Janse J., Levi M., ten Cate H., ten Cate J.W., van Deventer S.J.H. Regulation of interleukin-10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med. 180:1994;1985.
36. Van der Poll T., Coyle S.M., Barbosa K., Braxton C.C., Lowry S.F. Epinephrine inhibits tumor necrosis factor-α and potentiates interleukin-10 production during human endotoxemia. J Clin Invest. 97:1996;713.
37. Gerard C., Bruyns C., Marchant A., et al. Interleukin-10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med. 177:1993;547.
38. Leeuwenberg J.F.M., Jeunhomme T.M.A.A., Buurman W.A. Slow release of soluble TNF receptors by monocytes in vitro. J Immunol. 152:1994;4036.
39. Mowal A.M., Viney J.L. The anatomical basis of intestinal immunity. Immunol Rev. 156:1997;145.
40. Fong Y., Marano M.A., Barber A., et al. Total parenteral nutrition and bowel rest modify the metabolic response to endotoxin in humans. Ann Surg. 210:1989;449.
41. Reynolds J.V., Kanwar S., Welsh F.K.S., et al. Does the route of feeding modify gut barrier function and clinical outcome in patients after major upper gastrointestinal surgery? JPEN. 21:1997;196.
42. Lin M.T., Saito H., Fukushima R., et al. Preoperative total parenteral nutrition influences postoperative systemic cytokine responses after colorectal surgery. Nutrition. 13:1997;8.
43. Lemaire L.C.J.M., van Lanschot J.J.B., Stoutenbeek C.P., Deventer S.J.H., Wells C.L., Gouma D.J. Bacterial translocation in multiple organ failure cause or epiphenomenon still unproven . Br J Surg. 84:1997;1340.
44. Frost P., Bihari D. The route of nutritional support in the critically ill physiological and economical considerations . Nutrition. 13:1997;58S.
45. Kudsk K.A. Gut mucosal nutritional support enteral nutrition as primary therapy after multiple system trauma . Gut. 1:1994;S52.
46. Griffiths R.D., Jones C., Palmer T.E.A. Six-month outcome of critically ill patients given glutamine-supplemented parenteral nutrition. Nutrition. 13:1997;295.
47. Van der Hulst R.R.W.J., von Meyenfeldt M.F., Tiebosch A., Buurman W.A., Soeters P.B. Glutamine and intestinal immune cells in humans. JPEN. 21:1997;310.
48. Lin E., Goncalves J.A., Lowry S.F. Efficacy of nutritional pharmacology in surgical patients. Curr Opin Clin Nutr Metab Care. 1:1997;41.
49. Swails W.S., Kenler A.S., Driscoll D.F. Effect of a fish oil structured lipid-based diet on prostaglandin release from mononuclear cells in cancer patients after surgery. JPEN. 21:1997;266.
50. Gianotti L., Braga M., Vignali A., et al. Effect of route of delivery and formulation of postoperative nutritional support in patients undergoing major operations for malignant neoplasms. Arch Surg. 132:1997;1222.
51. Beaumier L., Castillo L., Ajami A.M., Young V.R. Urea cycle intermediate kinetics and nitrate excretion at normal and therapeutic intakes of arginine in humans. Endocrinol Metab. 32:1995;E864.
52. Barbul A., Lazarou S.A., Efron D.T., Wasserkrug H.L., Efron G. Arginine enhances wound healing and lymphocyte response in humans. Surgery. 106:1990;331.
53. Khan A.L., Richardson S., Drews J., et al. Polyadenylic-polyuridylic acid enhances the natural cell-mediated cytotoxicity in patients with breast cancer undergoing mastectomy. Surgery. 118:1995;531.
54. Senkal M., Mumme A., Eickhoff U., et al. Early postoperative enteral immunonutrition clinical outcome and cost-comparison analysis in surgical patients . Crit Care Med. 25:1997;1489.
55. Saffle J.R., Wiebke G., Jennings K., Morris S.E., Barton R.G. Randomized trial of immune-enhancing enteral nutrition in burn patients. J Trauma. 42:1997;793.
56. Heslin M.J., Latkany L., Leung D., et al. A prospective randomized trial of early enteral feeding after resection of upper GI malignancy. Ann Surg. 226:1997;567.